Efficacy of a Dietary Supplement (Aqualief®) in Xerostomic Patients

Quality of Life Clinical Trial

— Aqualief  

Official title:

Effetti Sulla Salivazione a Seguito Della Somministrazione di un Integratore Alimentare (Aqualief®) a Base di Carnosina ed Hibiscus Nei Soggetti Xerostomici: Studio Multicentrico, Randomizzato, in Doppio Cieco, Controllato Verso Placebo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03612414
• Other study ID #: Prot.49 May 31st, 2016
• Status: Completed
• Phase: N/A
• Start date: June 15, 2016
• Est. completion date: December 15, 2017

Study information

• Verified date: July 2018
• Source: Università degli Studi dell'Insubria
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Xerostomia is defined as the subjective complaint of dry mouth. Symptoms of dry mouth may range from mild oral discomfort to significant oral disease that can compromise patients' health, dietary intake and quality of life. Xerostomia is accompanied by numerous signs and symptoms mainly in the mucous membranes, lips, tongue, salivary glands and teeth.

This study was designed to verify efficacy and safety of a novel dietary supplement (Aqualief),designed with the aim of stabilizing the saliva flux and pH at a neutral level and to improve the acid buffering capacity of saliva.

Description:

Sixty patients with xerostomia (grade 1-2 according to RTOG/EORTC) from different etiologies were recruited at the Clinica Odontoiatrica dell'Università degli studi dell'Insubria (Varese, Italy). Exclusion criteria were subjects under treatment using drugs to treat hyposalivation (e.g. pilocarpine) and xerostomia grade ≥ 3. Patients with severe hyposalivation were excluded (saliva flow rate at baseline <0.1 ml min-1) due to their inability to dissolve the tablet formulation.

Written informed consent was received from all patients before study initiation. The study was conducted in accordance with the principles laid out by the Declaration of Helsinki 1964 and its subsequent amendments and with the International Committee on Harmonization Guidelines for Good Clinical Practice and in compliance with local ethical and legal requirements. The study was approved by the ethics committee at the participating site.

The study was a prospective, randomized, double-blind, placebo-controlled trial undertaken at the Clinica Odontoiatrica dell'Università degli Studi dell'Insubria (Varese, Italy). Eligible patients who had developed xerostomia RTOG/EORTC grade 1-2 were randomized in a 1:1 ratio, with one group receiving three Aqualief tablets (after meals: breakfast, lunch, dinner) daily for 6 days. The second group received a placebo tablet given with the same regimen. The primary objective of the study was to assess the safety and efficacy of Aqualief in stabilizing the saliva pH at a neutral level compared with placebo. The secondary objective was to determine whether Aqualief induced an increase of unstimulated or stimulated saliva and in ameliorating the symptoms related to oral dryness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 15, 2017
• Est. primary completion date: October 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects of both sex

• Age = a 18 years

• Able to understand and sign the Informed Consent, and fill in the patient's diary

• Subjects suffering from Xerosotmia Grade 1-2 (according to RTOG/EORTC scale)

• Sjögren Sindrome

• Lambert-Eaton Sindrome

• Diabetes mellitus and low metabolic control

• Anxiety

• Alcool abuse

• Salivary glands trauma

• Radio and Chemotherapy for head & neck cancer

• Methamphetamine, cannabis, heroin abuse

• Xerostomia caused by (single and concomitant, i.e. Anti-depressive and anxyolitic drugs; Antihistaminic drugs; Decongestive drugs; Antihypertensive drugs; Muscle relaxants; Urinary incontinence drugs; Drugs for Parkinson treatment)

• Subjects affected by paradental pathology diagnosed according to AAOP criteria, PSR 2-3

Exclusion Criteria:

• Contraindication and/or Hypersensitivity to product's components, and in particular carnosine and Hibiscus

• Subjects that are under treatment with products or drugs ( ie pilocarpin) for hypofunctionality of salivary glands

• Subjects with total ablation of salivary glands caused by chemo or radiotherapy

• Use of experimental drugs during 30 days before the enrolment or during the study

• Conditions that can interfere with the study

• Xerostomia grade 3 or higher

Related Conditions & MeSH terms

• pH
• Quality of Life
• Saliva
• Xerostomia
• Xerostomia Due to Hyposecretion of Salivary Gland

Intervention

Dietary Supplement:
• Aqualief
Three tablets/day
• Placebo
Three tablets/day

Locations

Country	Name	City	State
Italy	Università degli Studi dell'Insubria	Varese

Sponsors (1)

Lead Sponsor	Collaborator
Università degli Studi dell'Insubria

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of Aqualief on salivation	Changes in saliva production is measured (ml)	Change from baseline to 6 days of treatment
Secondary	Safety of Aqualief	Incidence of Treatment-Emergent Adverse Events	Occurrence of Adverse Events over the 6 days of treatment
Secondary	Effect of Aqualief on dry mouth symptoms	Evaluate the effect of treatments dry mouth symptoms trough Dry Mouth Questionnaire (Thomson Questionnaire)	Change from baseline to 6 days of treatment
Secondary	Effect of Aqualief on the pH of saliva	Changes of saliva pH is measured	Change from baseline to 6 days of treatment